Guj. Terce Labs.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE499G01013
NSEID:
BSEID: 524314

INR

49.04

0.24 (0.49%)

BSENSE

Dec 23

BSE+NSE Vol: 51

{
  "main_header": {
    "sid": 890385,
    "name": "Guj. Terce Labs.",
    "stock_name": "Guj. Terce Labs.",
    "full_name": "Gujarat Terce Laboratories Ltd",
    "name_url": "stocks-analysis/guj-terce-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "49.04",
    "chg": 0.24,
    "chgp": "0.49%",
    "dir": 1,
    "prev_price": "48.80",
    "mcapval": "36.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524314,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE499G01013",
    "curr_date": "Dec 23",
    "curr_time": "",
    "bse_nse_vol": "51 ",
    "exc_status": "Active",
    "traded_date": "Dec 23, 2025",
    "traded_date_str": "2025 12 23",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/guj-terce-labs-890385-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Guj. Terce Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-terce-labs-fallingrising-3764311",
        "imagepath": "",
        "date": "2025-12-20 02:24:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Momentum and Outperformance</strong></p>\n<p>The stock has demonstrated strong momentum over the past week and month, delivering returns of 7.98% and 11.64% respectively, significantly outperforming the Sensex which declined marginally in the same periods. This recent surge is further underscored by the stock’s consecutive gains over the last two days, accumulating a 12.21% return in that timeframe. On 19-Dec, the stock reached an intraday high of ₹48.50, marking a 6.62% increase from its low of ₹43.90, indicating robust intraday volatility and investor interest.</p>\n<p>Despite this positive short-term trend, the weighted average price suggests that a greater volume of shares traded closer to the day’s low, hinting at some selling pressure or cautious profit-taking even amid ..."
      },
      {
        "title": "Gujarat Terce Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gujarat-terce-laboratories-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3754854",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GujaratTerceLab_mojoScore_3754854.png",
        "date": "2025-12-10 08:16:27",
        "description": "Gujarat Terce Laboratories has experienced a revision in its market assessment driven by nuanced changes across quality, valuation, financial trends, and technical indicators. Despite recent positive quarterly financial results, the company’s longer-term fundamentals and technical outlook present a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Gujarat Terce Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gujarat-terce-laboratories-downgraded-to-sell-amid-mixed-technicals-and-weak-fundamentals-3747788",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GujaratTerceLab_mojoScore_3747788.png",
        "date": "2025-12-05 08:09:35",
        "description": "Gujarat Terce Laboratories has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators and fundamental financial data. While recent trading activity shows signs of stabilisation, underlying financial metrics continue to present challenges, prompting a nuanced reassessment of the company's investment profile."
      },
      {
        "title": "How has been the historical performance of Guj. Terce Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-terce-labs-3747111",
        "imagepath": "",
        "date": "2025-12-04 22:49:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the three fiscal years ending March 2021, Guj. Terce Labs. witnessed a notable decline in net sales, falling from ₹37.54 crores in March 2020 to ₹25.18 crores in March 2021. This represents a significant contraction of approximately 33%, reversing the growth seen in the previous year when sales had increased from ₹31.03 crores in March 2019 to ₹37.54 crores in March 2020. The absence of other operating income throughout these years indicates that the company’s revenue streams are solely dependent on its core operations.</p>\n<p>Cost management has been a mixed bag. Raw material costs and purchase of finished goods decreased in line with lower sales, but employee costs remained relatively high, only marginally reduced from ₹15.13 crores in ..."
      },
      {
        "title": "Is Guj. Terce Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-guj-terce-labs-overvalued-or-undervalued-3709851",
        "imagepath": "",
        "date": "2025-11-18 08:22:54",
        "description": "As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms.\n\nIn comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contra..."
      },
      {
        "title": "How has been the historical performance of Guj. Terce Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-terce-labs-3683702",
        "imagepath": "",
        "date": "2025-11-09 22:47:36",
        "description": "Answer:\nThe historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year.\n\nBreakdown:\nGuj. Terce Labs reported net sales of 25.18 Cr in March 2021, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also decreased from 36.86 Cr in March 2020. This led to an operating profit (PBDIT) of -1.96 Cr in March 2021, contrasting with a profit of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax fell to -2.53 Cr in March 2021, down from 0.44 Cr in March 2020. The profit after tax also reflected this downturn, resulting in a loss of 2.52 Cr in ..."
      },
      {
        "title": "Are Guj. Terce Labs. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-guj-terce-labs-latest-results-good-or-bad-3683316",
        "imagepath": "",
        "date": "2025-11-09 19:14:31",
        "description": "Gujarat Terce Laboratories' latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹10.13 crores, reflecting marginal growth of 1.91% sequentially, while year-on-year performance remained essentially flat at 0.20%. However, the most concerning aspect was the sharp contraction in operating profit margins, which fell to 5.33% from 16.40% in the previous quarter, indicating severe operational stress.\n\nNet profit for the quarter was ₹0.45 crores, which represents a substantial decline of 71.88% compared to the previous quarter. This decline in profitability highlights difficulties in cost management, particularly as employee costs rose significantly, consuming nearly 39% of revenues. The company's return on equity (ROE) has also been notably weak, with a recent figure of -15.34%, further underscoring the operational distress.\n\nDespite the company mainta..."
      },
      {
        "title": "Gujarat Terce Laboratories Q2 FY26: Profit Plunge Raises Serious Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/gujarat-terce-laboratories-q2-fy26-profit-plunge-raises-serious-concerns-3682515",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratTerceLab_quaterlyResult_3682515.png",
        "date": "2025-11-08 18:02:17",
        "description": "Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹32.00 crores, reported deeply concerning quarterly results for Q2 FY26 (Jul-Sep'25), with net profit plummeting 71.88% quarter-on-quarter to ₹0.45 crores from ₹1.60 crores in Q1 FY26. The stock, currently trading at ₹45.98, has collapsed 45.25% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers."
      },
      {
        "title": "Why is Guj. Terce Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-terce-labs-fallingrising-3676862",
        "imagepath": "",
        "date": "2025-11-06 22:31:09",
        "description": "As of 06-Nov, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 44.15, which reflects a decrease of Rs 1.71 or 3.73%. The stock has been underperforming, having lost 5.07% over the last two days and is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's performance today has underperformed its sector by 2.96%. Over the past week, the stock has decreased by 6.36%, and year-to-date, it has plummeted by 47.94%, showcasing significant underperformance compared to the Sensex, which has gained 6.62% during the same period. There is also a notable decline in investor participation, with delivery volume dropping by 83.32% against the 5-day average, suggesting reduced interest in the stock.\n\nBroader Market Context: In the context of the broader market, Gujarat Terce Laboratories Ltd's recent performance contrasts sharply with the Sen..."
      }
    ],
    "total": 169,
    "sid": "890385",
    "stock_news_url": "https://www.marketsmojo.com/news/gujarat-terce-laboratories-890385"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
      "datetime": "17-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aalap Natubhai Prajapati",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011",
      "datetime": "17-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aalap Natubhai Prajapati",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "16-Dec-2025",
      "details": "The Board of Directors of the Company on 16 December 2025 has approved the conversion of 371000 fully convertible warrants into 371000 Equity shares of face value of Rs. 10/- each issued price of Rs. 37.70/- per share allotted to Mr. Aalap Prajapati Promoter & Managing Director of the Company.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Guj. Terce Labs. falling/rising?

2025-12-20 02:24:32

Short-Term Price Momentum and Outperformance

The stock has demonstrated strong momentum over the past week and month, delivering returns of 7.98% and 11.64% respectively, significantly outperforming the Sensex which declined marginally in the same periods. This recent surge is further underscored by the stock’s consecutive gains over the last two days, accumulating a 12.21% return in that timeframe. On 19-Dec, the stock reached an intraday high of ₹48.50, marking a 6.62% increase from its low of ₹43.90, indicating robust intraday volatility and investor interest.

Despite this positive short-term trend, the weighted average price suggests that a greater volume of shares traded closer to the day’s low, hinting at some selling pressure or cautious profit-taking even amid ...

Gujarat Terce Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals

2025-12-10 08:16:27

Gujarat Terce Laboratories has experienced a revision in its market assessment driven by nuanced changes across quality, valuation, financial trends, and technical indicators. Despite recent positive quarterly financial results, the company’s longer-term fundamentals and technical outlook present a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Gujarat Terce Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-05 08:09:35

Gujarat Terce Laboratories has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators and fundamental financial data. While recent trading activity shows signs of stabilisation, underlying financial metrics continue to present challenges, prompting a nuanced reassessment of the company's investment profile.

How has been the historical performance of Guj. Terce Labs.?

2025-12-04 22:49:00

Revenue and Profitability Trends

Over the three fiscal years ending March 2021, Guj. Terce Labs. witnessed a notable decline in net sales, falling from ₹37.54 crores in March 2020 to ₹25.18 crores in March 2021. This represents a significant contraction of approximately 33%, reversing the growth seen in the previous year when sales had increased from ₹31.03 crores in March 2019 to ₹37.54 crores in March 2020. The absence of other operating income throughout these years indicates that the company’s revenue streams are solely dependent on its core operations.

Cost management has been a mixed bag. Raw material costs and purchase of finished goods decreased in line with lower sales, but employee costs remained relatively high, only marginally reduced from ₹15.13 crores in ...

Is Guj. Terce Labs. overvalued or undervalued?

2025-11-18 08:22:54

As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms. In comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contra...

How has been the historical performance of Guj. Terce Labs.?

2025-11-09 22:47:36

Answer: The historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year. Breakdown: Guj. Terce Labs reported net sales of 25.18 Cr in March 2021, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also decreased from 36.86 Cr in March 2020. This led to an operating profit (PBDIT) of -1.96 Cr in March 2021, contrasting with a profit of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax fell to -2.53 Cr in March 2021, down from 0.44 Cr in March 2020. The profit after tax also reflected this downturn, resulting in a loss of 2.52 Cr in ...

Are Guj. Terce Labs. latest results good or bad?

2025-11-09 19:14:31

Gujarat Terce Laboratories' latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹10.13 crores, reflecting marginal growth of 1.91% sequentially, while year-on-year performance remained essentially flat at 0.20%. However, the most concerning aspect was the sharp contraction in operating profit margins, which fell to 5.33% from 16.40% in the previous quarter, indicating severe operational stress. Net profit for the quarter was ₹0.45 crores, which represents a substantial decline of 71.88% compared to the previous quarter. This decline in profitability highlights difficulties in cost management, particularly as employee costs rose significantly, consuming nearly 39% of revenues. The company's return on equity (ROE) has also been notably weak, with a recent figure of -15.34%, further underscoring the operational distress. Despite the company mainta...

Gujarat Terce Laboratories Q2 FY26: Profit Plunge Raises Serious Concerns

2025-11-08 18:02:17

Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹32.00 crores, reported deeply concerning quarterly results for Q2 FY26 (Jul-Sep'25), with net profit plummeting 71.88% quarter-on-quarter to ₹0.45 crores from ₹1.60 crores in Q1 FY26. The stock, currently trading at ₹45.98, has collapsed 45.25% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers.

Why is Guj. Terce Labs. falling/rising?

2025-11-06 22:31:09

As of 06-Nov, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 44.15, which reflects a decrease of Rs 1.71 or 3.73%. The stock has been underperforming, having lost 5.07% over the last two days and is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's performance today has underperformed its sector by 2.96%. Over the past week, the stock has decreased by 6.36%, and year-to-date, it has plummeted by 47.94%, showcasing significant underperformance compared to the Sensex, which has gained 6.62% during the same period. There is also a notable decline in investor participation, with delivery volume dropping by 83.32% against the 5-day average, suggesting reduced interest in the stock. Broader Market Context: In the context of the broader market, Gujarat Terce Laboratories Ltd's recent performance contrasts sharply with the Sen...

View All News

Announcement

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011

17-Dec-2025 | Source : BSE

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aalap Natubhai Prajapati

Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011

17-Dec-2025 | Source : BSE

The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aalap Natubhai Prajapati

Announcement under Regulation 30 (LODR)-Allotment

16-Dec-2025 | Source : BSE

The Board of Directors of the Company on 16 December 2025 has approved the conversion of 371000 fully convertible warrants into 371000 Equity shares of face value of Rs. 10/- each issued price of Rs. 37.70/- per share allotted to Mr. Aalap Prajapati Promoter & Managing Director of the Company.